BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumada H, Sato K, Takehara T, Nakamuta M, Ishigami M, Chayama K, Toyota J, Suzuki F, Nakayasu Y, Ochi M. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. Hepatol Res. 2015;45:745-754. [PMID: 25196718 DOI: 10.1111/hepr.12416] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Igarashi A, Furusyo N, Ogawa E, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J. Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan. BMJ Open 2019;9:e023405. [PMID: 31221866 DOI: 10.1136/bmjopen-2018-023405] [Reference Citation Analysis]
2 Sasazuki S, Inoue M, Shimazu T, Wakai K, Naito M, Nagata C, Tanaka K, Tsuji I, Sugawara Y, Mizoue T, Matsuo K, Ito H, Tamakoshi A, Sawada N, Nakayama T, Kitamura Y, Sadakane A, Tsugane S; Development and Evaluation of Cancer Prevention Strategies in Japan. Evidence-based cancer prevention recommendations for Japanese. Jpn J Clin Oncol 2018;48:576-86. [PMID: 29659926 DOI: 10.1093/jjco/hyy048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
3 Kawaguchi T, Komori A, Fujisaki K, Nishiguchi S, Kato M, Takagi H, Tanaka Y, Notsumata K, Mita E, Nomura H, Shibatoge M, Takaguchi K, Hattori T, Sata M, Koike K. Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia. Exp Ther Med 2019;18:596-604. [PMID: 31258695 DOI: 10.3892/etm.2019.7616] [Reference Citation Analysis]
4 Bourlière M, Benali S, Ansaldi C, Le Folgoc G, Riso A, Lecomte L. Optimal therapy of genotype-2 chronic hepatitis C: what’s new? Liver Int. 2015;35 Suppl 1:21-26. [PMID: 25529084 DOI: 10.1111/liv.12711] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World J Gastroenterol 2018; 24(13): 1478-1485 [PMID: 29632428 DOI: 10.3748/wjg.v24.i13.1478] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. Antimicrob Agents Chemother 2016;60:3563-78. [PMID: 27021330 DOI: 10.1128/AAC.02929-15] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
7 Kumada H, Mochida S, Nakamuta M, Suzuki F, Yagi T, Takasaki R, Okai M, Kamiya N, Okada Y, Hirota S, Orihashi M, Ochi M, Chayama K. Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression. Hepatol Res 2018;48:184-92. [PMID: 28497489 DOI: 10.1111/hepr.12914] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Igarashi A, Tang W, Cure S, Guerra I, Marié L, Lopresti M, Tsutani K. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Curr Med Res Opin 2017;33:1-10. [PMID: 27608157 DOI: 10.1080/03007995.2016.1222512] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
9 Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM. Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance. Antimicrob Agents Chemother 2015;59:7426-36. [PMID: 26392503 DOI: 10.1128/AAC.01953-15] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]